Kevin joined Relievant in September 2017 and serves as President and Chief Executive Officer. Prior to Relievant, Kevin was an Operating Partner at Versant Ventures and Chairman and CEO of Metavention, Inc., a clinical-stage medical device company focused on the development of interventional therapies for the treatment of type 2 diabetes. Prior to Metavention, Kevin was President and CEO of Cameron Health, developer of the first and only subcutaneous implantable defibrillator, until its acquisition by Boston Scientific in 2012. Prior to Cameron Health, he was the Chief Commercial Officer of Visiogen, Inc., a venture-backed ophthalmology company which was acquired by Abbott Medical Optics in 2009. Previous to Visiogen, he spent 16 years at Medtronic, where he held leadership positions in the CRM, Neurostimulation and Cardiac Surgery businesses in the US and Europe.
Kevin received his MBA from Northwestern University and a BBA from the University of Wisconsin. Kevin serves as Chairman of the Board of Metavention and serves as an independent board member at Veran Medical Technologies and the Courage Kenny Rehabilitation Institute Foundation.
